Clinical trials: Non-hodgkin Lymphoma,B Cell
Non-Hodgkin's B-cell Lymphoma
Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma
This is an active treatment, extended access study open solely to those subjects who have successfully completed the Core and Repeat Dosing portions of the MT-3724_NHL_001_US clinical study and who, in the investigator's…
- Trial name
- NCT02715843
- Testing
- MT-3724
- Where
- 3 sites in United States
- Sponsor
- Molecular Templates, Inc.
Lymphoma
High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Bone marrow transplantation may allow doctors to give higher doses of chemotherapy drugs and kill more…
- Trial name
- NCT00003578
- Testing
- CHOP regimen, carmustine, cyclophosphamide
- Where
- 72 sites in Czechia, Denmark and 2 more
- Volunteers
- 500 people
- Sponsor
- Lymphoma Trials Office
Diffuse Large B-Cell Lymphoma
DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
This study will treat patients with diffuse large B-cell lymphoma (DLBCL). It will assess the anti-tumor efficacy and safety of DZD8586 combination therapy by using objective response rate and the incidence and severity of…
- Trial name
- NCT07059650
- Testing
- DZD8586+R-CHOP, DZD8586+R-GemOx, DZD8586+BR
- Where
- 13 sites in China
- Volunteers
- 150 people
- Sponsor
- Dizal Pharmaceuticals
Extranodal NK/T-cell Lymphoma
B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma
Study Title: Phase I/II study of brentuximab vedotin and methotrexate/ L-asparaginase/ dexamethasone (B-MAD) chemotherapy in patients with newly-diagnosed Extranodal NK/T-cell Lymphoma Phase: I/II Number of Patients: 36 Study…
- Trial name
- NCT03246750
- Testing
- B-MAD chemotherapy
- Where
- Thailand
- Volunteers
- 34 people
- Sponsor
- The Thai Lymphoma Study Group
NSCLC, SCLC
Study of Oral MRT-2359 in Selected Cancer Patients
This Phase 1/2, open-label, multicenter study is conducted in patients with previously treated selected solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), high-grade neuroendocrine cancer…
- Conditions
- NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL
- Trial name
- NCT05546268
- Testing
- Oral MRT-2359
- Where
- 17 sites in United States
- Volunteers
- 174 people
- Sponsor
- Monte Rosa Therapeutics, Inc
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma
This is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of firicabtagene autoleucel (firi-cel), a…
- Trial name
- FIRCE-1 (NCT05972720)
- Testing
- Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)
- Where
- 31 sites in United States
- Volunteers
- 101 people
- Sponsor
- CARGO Therapeutics
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes.
- Conditions
- B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia
- Trial name
- NCT03959085
- Testing
- Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration
- Where
- 231 sites in United States, Australia and 3 more
- Volunteers
- 5,951 people
- Sponsor
- Children's Oncology Group
B Cell Non-Hodgkin's Lymphoma
A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma
This is a single-center, open-label study to evaluate the safety and efficacy of C-CAR039 in relapsed and/or refractory B cell Non-Hodgkin's Lymphoma patients.
- Trial name
- NCT05149391
- Testing
- CD19/CD20-directed Chimeric Antigen Receptor T Cells
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Peking University
Gastric Cancer, Head and Neck Cancer
Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer
RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating…
- Conditions
- Gastric Cancer, Head and Neck Cancer, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT01147991
- Testing
- EBNA1 C-terminal/LMP2 chimeric protein-expressing recombinant modified vaccinia Ankara vaccine, laboratory biomarker analysis, pharmacological study
- Where
- 3 sites in United Kingdom
- Volunteers
- 16 people
- Sponsor
- Cancer Research UK
B-cell Non-Hodgkin's Lymphoma (B-NHL)
Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL
The main objective of this study is to observe and evaluate the safety and tolerability of the XP-006 personalized tumor mRNA vaccine for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.
- Trial name
- XP-006 (NCT07334574)
- Testing
- Personalized neoantigen tumor vaccine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Lymphoma, B-Cell
Indication to Transplant Patients With High Risk B Cells Lymphoma in Metabolic Complete Remission?
The autograft of patients with prognostically unfavourable B-cells lymphoma cells in first remission remains controversial, in particular since the association of Rituximab with chemotherapy.
- Trial name
- NCT03681938
- Testing
- Autograft
- Where
- France
- Volunteers
- 183 people
- Sponsor
- Institut Paoli-Calmettes
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
This phase I trial studies the side effects and best dose of monoclonal antibody therapy before stem cell transplant in treating patients with relapsed or refractory lymphoid malignancies.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01678443
- Testing
- indium In 111 anti-CD45 monoclonal antibody BC8, yttrium Y 90 anti-CD45 monoclonal antibody BC8, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Fred Hutchinson Cancer Center
Lymphoma, Large-Cell
Early Evaluation of the Response of Large B Cell Non Hodgkin's Lymphoma to Chemotherapy by PET/CT
Patients affected with non-Hodgkin's large B-cell lymphoma are treated by chemotherapy. The evaluation of the response to this treatment is made by Positron Emission Tomography (PET/CT) in many centres where this technology is…
- Trial name
- NCT00256490
- Testing
- PET/CT 20 days after the first cycle of chemotherapy
- Where
- Canada
- Volunteers
- 82 people
- Sponsor
- Eric Turcotte
Diffuse Large B-cell Lymphoma
the Effect of Broken Ganoderma Lucidum Spore Powder on Quality of Life and Immune Function in Patients With Diffuse Large B-cell Lymphoma After Chemotherapy
The purpose of this study was to explore the effect of broken Ganoderma lucidum spore powder on improving the quality of life and immune recovery of patients after chemotherapy.
- Trial name
- NCT04914143
- Testing
- broken Ganoderma lucidum spore powder
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Diffuse Large B-Cell Lymphoma
G-Pola-ZLP in Diffuse Large B-Cell Lymphoma
The goal of this phase 2 trial is to test the safety and efficacy of G-Pola-ZLP as induction therapy in patients with DLBCL.
- Trial name
- NCT06665217
- Testing
- Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy
- Volunteers
- 80 people
- Sponsor
- Navy General Hospital, Beijing
B-Cell ALL, ALL (Acute B-Lymphoblastic Leukemia)
BLinatumomab and iNKT in Relapsed B-Cell ALL
This is an open-label, single-arm pilot study evaluating agenT-797, an invariant natural killer T-cell (iNKT) therapy, in combination with routine clinical care blinatumomab in subjects with Philadelphia chromosome-negative…
- Conditions
- B-Cell ALL, ALL (Acute B-Lymphoblastic Leukemia), Philadelphia Chromosome-Negative Lymphoblastic Leukemia, CD19-positive B-cell Acute
- Trial name
- BLINK B-ALL (NCT07869368)
- Testing
- Invariant Natural Killer T Cell Therapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Marginal Zone Lymphoma, Follicular Lymphoma
BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)
This was a multicenter, open-label, phase 2 study to evaluate efficacy, safety, and tolerability of BGB-3111 (zanubrutinib) 160 milligrams (mg) twice daily (BID) in combination with rituximab in Chinese participants with…
- Conditions
- Marginal Zone Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma
- Trial name
- NCT03520920
- Testing
- Zanubrutinib, Rituximab
- Where
- 4 sites in China
- Volunteers
- 41 people
- Sponsor
- BeiGene
Diffuse Large B-cell Lymphoma
Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over
This is Phase II prospective trial of addition of rituximab to reduced dose CHOP chemotherapy in DLBC L patients aged 65 years and over.
- Trial name
- NCT02792491
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
- Volunteers
- 57 people
- Sponsor
- Pusan National University Hospital
Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
This phase II trial tests the effect of nemtabrutinib in combination with rituximab in treating patients with marginal zone lymphoma.
- Conditions
- Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma, Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma
- Trial name
- NCT07583810
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- City of Hope Medical Center
Burkitt Lymphoma
LMBA02 Protocol for Patients With a Burkitt Lymphoma
To explore in a multicenter international prospective randomized study (phase III) whether rituximab combined with the standard French LMB chemotherapy scheme results in a higher rate of EFS than the LMB chemotherapy scheme alone…
- Trial name
- NCT00180882
- Testing
- rituximab
- Where
- France
- Volunteers
- 260 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.